These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Ibrutinib dose modifications in the management of CLL. Hardy-Abeloos C; Pinotti R; Gabrilove J J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582 [TBL] [Abstract][Full Text] [Related]
11. Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study). Abrisqueta P; Loscertales J; Terol MJ; Ramírez Payer Á; Ortiz M; Pérez I; Cuellar-García C; Fernández de la Mata M; Rodríguez A; Lario A; Delgado J; Godoy A; Arguiñano Pérez JM; Berruezo MJ; Oliveira A; Hernández-Rivas JÁ; García Malo MD; Medina Á; García Martin P; Osorio S; Baltasar P; Fernández-Zarzoso M; Marco F; Vidal Manceñido MJ; Smucler Simonovich A; López Rubio M; Jarque I; Suarez A; Fernández Álvarez R; Lancharro Anchel A; Ríos E; Losada Castillo MDC; Pérez Persona E; García Muñoz R; Ramos R; Yáñez L; Bello JL; Loriente C; Acha D; Villanueva M Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e985-e999. PubMed ID: 34511320 [TBL] [Abstract][Full Text] [Related]
12. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia. Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255 [TBL] [Abstract][Full Text] [Related]
13. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572 [TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes in Patients with Multi-Hit Brieghel C; Aarup K; Torp MH; Andersen MA; Yde CW; Tian X; Wiestner A; Ahn IE; Niemann CU Clin Cancer Res; 2021 Aug; 27(16):4531-4538. PubMed ID: 33963002 [TBL] [Abstract][Full Text] [Related]
15. Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation. Yang S; Zhu R; Li N; Feng Y; Zuo R; Gale RP; Huang X Acta Haematol; 2022; 145(1):54-62. PubMed ID: 34569486 [TBL] [Abstract][Full Text] [Related]
16. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M; Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421 [TBL] [Abstract][Full Text] [Related]
17. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Kittai AS; Miller C; Goldstein D; Huang Y; Abruzzo LV; Beckwith K; Bhat SA; Bond DA; Grever MR; Heerema NA; Rogers KA; Ruppert AS; Byrd JC; Woyach JA Blood; 2021 Dec; 138(23):2372-2382. PubMed ID: 34314481 [TBL] [Abstract][Full Text] [Related]
18. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383 [TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. Allan JN; Shanafelt T; Wiestner A; Moreno C; O'Brien SM; Li J; Krigsfeld G; Dean JP; Ahn IE Br J Haematol; 2022 Feb; 196(4):947-953. PubMed ID: 34865212 [TBL] [Abstract][Full Text] [Related]
20. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. Hampel PJ; Call TG; Rabe KG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA Oncologist; 2020 Nov; 25(11):974-980. PubMed ID: 32886416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]